<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Oculis Holding Ag Ordinary Shares — News on 6ix</title>
    <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares</link>
    <description>Latest news and press releases for Oculis Holding Ag Ordinary Shares on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 20 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/oculis-holding-ag-ordinary-shares" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a5a478dffbe2df10b314.webp</url>
      <title>Oculis Holding Ag Ordinary Shares</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares</link>
    </image>
    <item>
      <title>Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-announces-completion-of-last-patient-visit-in-phase-3-diamond-program-with-ocs-01-eye-drops-for-the-treatment-of-diabetic-macular-edema</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-announces-completion-of-last-patient-visit-in-phase-3-diamond-program-with-ocs-01-eye-drops-for-the-treatment-of-diabetic-macular-edema</guid>
      <pubDate>Mon, 20 Apr 2026 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with</description>
    </item>
    <item>
      <title>Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-announces-european-medicines-agency-prime-designation-for-privosegtor-advancing-a-potential-firstinclass-neuroprotective-candidate-for-optic-neuritis</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-announces-european-medicines-agency-prime-designation-for-privosegtor-advancing-a-potential-firstinclass-neuroprotective-candidate-for-optic-neuritis</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the</description>
    </item>
    <item>
      <title>Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-to-present-at-upcoming-north-american-neuro-ophthalmology-society-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-to-present-at-upcoming-north-american-neuro-ophthalmology-society-annual-meeting</guid>
      <pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Oculis to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-to-participate-in-upcoming-investor-conferences-12</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-to-participate-in-upcoming-investor-conferences-12</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical</description>
    </item>
    <item>
      <title>Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-reports-q4-and-full-year-2025-financial-results-and-provides-company-update</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-reports-q4-and-full-year-2025-financial-results-and-provides-company-update</guid>
      <pubDate>Tue, 03 Mar 2026 21:05:00 GMT</pubDate>
      <description>ZUG, Switzerland, March 03, 2026 (GLOBE NEWSWIRE) -- Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2 2026 Key expansion in neuro-ophthalmology with Breakthrough Therapy designation granted to Privosegtor, propelling the PIONEER registrational program in optic neuropathies with a potential U.S. market o</description>
    </item>
    <item>
      <title>Oculis Appoints Katie Kazem as Chief Legal Officer</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-appoints-katie-kazem-as-chief-legal-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-appoints-katie-kazem-as-chief-legal-officer</guid>
      <pubDate>Tue, 17 Feb 2026 05:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a</description>
    </item>
    <item>
      <title>Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-showcase-transformative-late-stage-pipeline-neuro-ophthalmology-and-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-showcase-transformative-late-stage-pipeline-neuro-ophthalmology-and-0</guid>
      <pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
      <description>Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in</description>
    </item>
    <item>
      <title>Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-announces-u-fda-breakthrough-090000131</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-announces-u-fda-breakthrough-090000131</guid>
      <pubDate>Tue, 06 Jan 2026 09:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment...</description>
    </item>
    <item>
      <title>Oculis Reports Q3 2025 Financial Results and Provides Company Update</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-reports-q3-2025-financial-results-and-provides-company-update-2025-11-10-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-reports-q3-2025-financial-results-and-provides-company-update-2025-11-10-0</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in</description>
    </item>
    <item>
      <title>Oculis to Participate in Upcoming November Investor Conferences</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-participate-upcoming-november-investor-conferences-2025-11-05-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-participate-upcoming-november-investor-conferences-2025-11-05-0</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-announces-oversubscribed-110-million-financing-accelerate-privosegtor-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-announces-oversubscribed-110-million-financing-accelerate-privosegtor-0</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company</description>
    </item>
    <item>
      <title>Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-spotlight-transformative-late-stage-pipeline-eyecelerator-and-aao-2025-2025-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-spotlight-transformative-late-stage-pipeline-eyecelerator-and-aao-2025-2025-0</guid>
      <pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-accelerates-privosegtor-registrational-trials-acute-optic-neuritis-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-accelerates-privosegtor-registrational-trials-acute-optic-neuritis-0</guid>
      <pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
      <description>Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic</description>
    </item>
    <item>
      <title>Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-announces-presentation-phase-2-acuity-trial-results-privosegtor-acute-optic-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-announces-presentation-phase-2-acuity-trial-results-privosegtor-acute-optic-0</guid>
      <pubDate>Mon, 22 Sep 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis.</description>
    </item>
    <item>
      <title>Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-and-euretina-announce-winner-ramin-tadayoni-award-2025-2025-09-04-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-and-euretina-announce-winner-ramin-tadayoni-award-2025-2025-09-04-0</guid>
      <pubDate>Thu, 04 Sep 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-present-clinical-trial-results-diabetic-macular-edema-and-acute-optic-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-present-clinical-trial-results-diabetic-macular-edema-and-acute-optic-0</guid>
      <pubDate>Mon, 01 Sep 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA</description>
    </item>
    <item>
      <title>Oculis to Participate in Upcoming September Investor Conferences</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-participate-upcoming-september-investor-conferences-2025-08-28-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-participate-upcoming-september-investor-conferences-2025-08-28-0</guid>
      <pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-appoints-mark-kupersmith-md-and-sebastian-wolf-md-phd-world-renowned-neuro-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-appoints-mark-kupersmith-md-and-sebastian-wolf-md-phd-world-renowned-neuro-0</guid>
      <pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2</description>
    </item>
    <item>
      <title>Oculis Reports Q2 2025 Financial Results and Provides Company Update</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-reports-q2-2025-financial-results-and-provides-company-update-2025-08-21-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-reports-q2-2025-financial-results-and-provides-company-update-2025-08-21-0</guid>
      <pubDate>Thu, 21 Aug 2025 04:00:00 GMT</pubDate>
      <description>Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and neuro-ophthalmologyOCS-01: Both pivotal Ph3 DIAMOND trials are fully enrolled,</description>
    </item>
    <item>
      <title>Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference</title>
      <link>https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-participate-upcoming-hc-wainwright-5th-annual-ophthalmology-virtual-0</link>
      <guid isPermaLink="true">https://6ix.com/company/oculis-holding-ag-ordinary-shares/news/oculis-participate-upcoming-hc-wainwright-5th-annual-ophthalmology-virtual-0</guid>
      <pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on</description>
    </item>
  </channel>
</rss>